Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani

Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution+sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. ro...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2001-04, Vol.19 (23-24), p.3104-3115
Main Authors: Paraguai de Souza, Edilma, Bernardo, Robson Roney, Palatnik, Marcos, Palatnik de Sousa, Clarisa Beatriz
Format: Article
Language:English
Subjects:
Adjuvants
Animals
Antibodies, Protozoan - biosynthesis
Antigens, Protozoan - administration & dosage
Antigens, Protozoan - isolation & purification
Biological and medical sciences
Female
Fundamental and applied biological sciences. Psychology
glycoprotein gp36
GP36 glycoprotein
Immunity, Cellular
Leishmania donovani
Leishmania donovani - immunology
Leishmaniasis, Visceral - immunology
Leishmaniasis, Visceral - prevention & control
Mice
Mice, Inbred BALB C
Murine visceral leishmaniasis
Native antigen
Protozoa
Protozoan Proteins - administration & dosage
Protozoan Proteins - immunology
Protozoan Proteins - isolation & purification
Protozoan Vaccines - administration & dosage
Saponin
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution+sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(01)00031-7